Biocon Chief Extols Moderna’s Success To Spur ‘Risk-Averse’ VCs in India
Executive Summary
Biocon chairperson Kiran Mazumdar-Shaw says that venture capital firms have, with their risk-averse approach, "failed" the biotech sector in India. The executive draws attention to how "bold" venture funds that backed mRNA technology a decade ago were reaping gains today.
You may also be interested in...
The Next Frontier: How India Could Up Its Game In Biopharma Innovation
Industry leaders and experts, including executives from McKinsey, Eight Roads Ventures and Novartis, share global best practices, insights and expectations around how India could accelerate its journey towards becoming a biopharma innovation hub.
Laronde Aims To Advance Its eRNA Therapies In Eight Weeks, And Has $440m To Help
The Flagship Pioneering-founded start-up will build a “Gigabase Factory” to go from idea to in vivo proof of concept within eight weeks by rapidly manufacturing and running preclinical tests for multiple constructs at once.
India IPR Realities: Pharma, Legal Heads Discuss Winds Of Change, ‘Damocles Sword’
Leaders from Novartis, Bayer, Sun Pharma, the Indian Pharmaceutical Alliance, Médecins Sans Frontières and Anand and Anand discuss India’s evolving intellectual property rights landscape, including pre-grant oppositions, enforcement action and other realities. Concerns around evergreening, restrictions on patent-eligible subject matter and compulsory licensing were also key talking points at a recent conference in Hyderabad.